Home Cart Sign in  
Chemical Structure| 1352226-88-0 Chemical Structure| 1352226-88-0

Structure of Ceralasertib
CAS No.: 1352226-88-0

Chemical Structure| 1352226-88-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Ceralasertib (AZD6738) is an orally active and bioavailable ATR kinase inhibitor with an IC50 of 1 nM.

Synonyms: AZD6738

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ceralasertib

CAS No. :1352226-88-0
Formula : C20H24N6O2S
M.W : 412.51
SMILES Code : N=[S@]([C@H]1C(C2=CC(N3[C@H](C)COCC3)=NC(C4=C5C(NC=C5)=NC=C4)=N2)C1)(C)=O
Synonyms :
AZD6738
MDL No. :MFCD28952790
InChI Key :OHUHVTCQTUDPIJ-JYCIKRDWSA-N
Pubchem ID :54761306

Safety of Ceralasertib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Ceralasertib

DNA
PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • ATR

    ATR, IC50:1 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
FaDu ATM-KO cells 1 μM 24 h Induced cell death PMC7299845
ATM-proficient mouse embryonic stem cells 350 nM 6 days To assess the sensitivity of ATM-proficient cells to Ceralasertib PMC8421211
ATM-deficient mouse embryonic stem cells 100 nM 6 days To assess the sensitivity of ATM-deficient cells to Ceralasertib PMC8421211
CD3/CD28 stimulated T-cells 1 μM 4 days To evaluate the effect of Ceralasertib on T-cell proliferation, the results showed that Ceralasertib significantly increased the expression of DNA damage markers. PMC10894296
IMR-5 0.05 μM 48 h To study the DNA damage effects of CX-5461 on neuroblastoma cells, results showed that CX-5461 induced DNA damage at low concentrations. PMC8578635
CHP-134 0.04 μM 3 days To study the cytotoxicity of CX-5461 on neuroblastoma cells, results showed that CX-5461 effectively induced apoptosis at low concentrations. PMC8578635
HEK293 cells >0.333 μM 24 h To evaluate the inhibitory effect of Ceralasertib on HRR, results showed that Ceralasertib could inhibit HRR PMC9359726
A549 cells >0.333 μM 72 h To evaluate the inhibitory effect of Ceralasertib on BIR repair, results showed that Ceralasertib could inhibit BIR repair PMC9359726
FaDu WT and FaDu ATM −/− cells 1 µM 24, 48, 72 h Investigated the sensitivity of ATM-deficient cells to Ceralasertib, showing that ATM −/− cells exhibited higher DNA damage, early apoptosis, and cell death after Ceralasertib treatment. PMC9481087
LL2-luc cells 1 µM 1 h To evaluate the effect of AZD6738 on the radiosensitivity of LL2-luc cells, results showed that AZD6738 enhanced the radiosensitivity of the cells. PMC7463250
LL2-luc cells 0.6 µM 72 h To evaluate the effect of AZD6738 on the proliferation of LL2-luc cells, results showed that AZD6738 has anti-proliferative effects. PMC7463250
HPAF-II 2000 nM 24 h To evaluate the effect of ATR inhibitor AZD6738 in combination with gemcitabine on DDR signaling pathways, results showed that DNA-PK-driven phosphorylation of Chk1 and Chk2 persisted. PMC7591912
MIA PaCa-2 500 nM 24 h To evaluate the effect of ATR inhibitor AZD6738 on the cell cycle, results showed that ATM-deficient cells exhibited increased intra-S phase accumulation and induced cell death. PMC7591912
MiaPaCa-2 cells 2 µM 24 h AZD6738 in combination with gemcitabine significantly induced phosphorylation of pRPA and γH2AX, indicating a strong induction of replication stress in these cells PMC6076438
K8484 cells 2 µM 7 h AZD6738 completely prevented gemcitabine-induced Chk1 phosphorylation and restored Cdk1 activity PMC6076438

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice CT26, MC38, 4T1, and A20 tumor models Oral 25 mg/kg Twice daily, 7 days on/7 days off To evaluate the antitumor effect of Ceralasertib under an intermittent dosing schedule, the results showed that Ceralasertib significantly inhibited tumor growth, and its antitumor effect was dependent on CD8+ T cells. PMC10894296
Mice Neuroblastoma xenograft model Intraperitoneal injection 5 mg/kg Once daily for 5 days, starting a second 5-day course on day 8, repeated every 21 days To study the anti-tumor activity of CX-5461 in vivo, results showed that CX-5461 significantly improved survival when combined with TOP1 inhibitors in orthotopic PDX mouse models. PMC8578635
Nude mice Granta-519 mantle cell lymphoma model Oral 50 mg/kg Once daily for 21 days To evaluate the antitumor activity of Ceralasertib in vivo, results showed significant tumor growth inhibition at 50 mg/kg dose PMC9359726
Mice Subcutaneous and orthotopic LL2-luc tumour models Intraperitoneal injection 15 mg/kg Daily for 6 days To evaluate the antitumor efficacy of AZD6738 in combination with radiotherapy in subcutaneous and orthotopic LL2-luc tumour models, results showed that AZD6738 enhanced the antitumor efficacy of radiotherapy, but the effect was limited in orthotopic tumour models. PMC7463250
Mice MIA PaCa-2 subcutaneous xenograft model Oral 50 mg/kg Once daily for 5 consecutive days a week for 3 weeks To evaluate the efficacy of ATR inhibitor AZD6738 monotherapy in ATM-deficient xenografts, results showed significant growth delay in ATM-deficient tumors. PMC7591912
Mice K8484 subcutaneous allograft model Oral 25 mg/kg 5 days/week for 3 weeks AZD6738 in combination with gemcitabine significantly inhibited tumor growth and extended survival in mice PMC6076438

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03770429 Leukemia|Myelodysplastic Syndr... More >>ome Less << PHASE1 RECRUITING 2025-05-31 BIDMC, Boston, Massachusetts, ... More >>02215, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, 02215, United States|Washington University, Saint Louis, Missouri, 63110, United States Less <<
NCT05469919 Advanced Solid Malignancies PHASE1 COMPLETED 2024-03-12 Research Site, Chuo-ku, 104-00... More >>45, Japan Less <<
NCT04564027 Advanced Solid Tumours PHASE2 ACTIVE_NOT_RECRUITING 2025-02-07 Research Site, Duarte, Califor... More >>nia, 91010, United States|Research Site, Los Angeles, California, 90089, United States|Research Site, San Francisco, California, 94115, United States|Research Site, Tampa, Florida, 33612, United States|Research Site, Indianapolis, Indiana, 46202, United States|Research Site, Baltimore, Maryland, 21231, United States|Research Site, Ann Arbor, Michigan, 48109, United States|Research Site, Las Vegas, Nevada, 89119, United States|Research Site, New York, New York, 10065, United States|Research Site, Ephrata, Pennsylvania, 17522, United States|Research Site, Philadelphia, Pennsylvania, 19104, United States|Research Site, Myrtle Beach, South Carolina, 29572, United States|Research Site, Bordeaux, 33076, France|Research Site, Dijon, 21079, France|Research Site, Lyon, 69373, France|Research Site, Vandoeuvre les Nancy, 54519, France|Research Site, Barcelona, 08036, Spain|Research Site, Madrid, 28050, Spain Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.42mL

0.48mL

0.24mL

12.12mL

2.42mL

1.21mL

24.24mL

4.85mL

2.42mL

References

 

Historical Records

Categories